Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration

Overview

Acronym
ALBION
Investigators
  • MD. Nikolaos Scarmeas

    Columbia University Medical Center

  • Dr. Eva Ntanasi

    Harokopio University

  • Dr. F Kalligerou

    Aiginition Hospital

Contacts
  • Aggeliki Fotopoulou

    Aiginition Hospital

General Design

Study design
Cohort
Start - End Year
2018 -
General Information on Follow Up (profile, frequency)
Recruitment Target
  • Individuals
Number of Participants
112
Number of Participants with Biological Samples
112

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Marker Paper

Kalligerou F, Ntanasi E, Voskou P, et al. Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data. Postgrad Med. 2019 Sep;131(7):501-508.

PUBMED 31483196

Timeline

Population

ALBION population

Selection Criteria

Minimum age
40
Countries
  • Greece
Territory
Athens
Health Status

Sources of Recruitment

Specific Population
  • Clinic patients

Sample Size

Number of Participants
112
Number of Participants with Biological Samples
112

Data Collection Events

# Name Description Start End
0 ALBION - Baseline 2018 2018
1 ALBION - Visit 2 2019 2019
2 ALBION - Visit 3 2020 2020
3 ALBION - Visit 4 2021 2021

Participating Studies

Acronym Name Study design Countries

Harmonization Initiatives Included

Acronym Name

Networks

Acronym Name Harmonization Initiatives Individual Studies

Datasets

Name Type Data Collection Events Variables
Last Update: 2021-08-10 20:25